A Tumor-Activatable Sorafenib Prodrug for Alleviating Hypoxia and Enhancing Hepatocellular Carcinoma Therapy
Source abstract
Abstract
Sorafenib (Sfb) is a widely used chemotherapy drug for the clinical treatment of hepatocellular carcinoma (HCC); however, its therapeutic effect is often hindered by inherent nonspecific toxicity and hypoxia-induced epithelial–mesenchymal transition (EMT). Besides, its inhibition of tumor angiogenesis further aggravates hypoxia, intensifying this challenge. Herein, we have developed a tumor-activatable Sfb prodrug (Sfb-Fca) to reverse the hypoxic tumor microenvironment for EMT alleviation and enhance therapeutic outcomes in HCC. Sfb-Fca consists of two components: the major moiety (Sfb) and the ferrocene acid (Fca) moiety, linked via a thioketal bond. This bond is cleaved in the presence of the elevated H 2 O 2 levels typical of cancer cells, releasing Sfb for chemotherapy and Fca for hypoxia modulation. Fca catalyzes the production of O 2 via a Fenton-like reaction, alleviating tumor hypoxia, reducing intracellular levels of HIF-1α and ZEB1 protein, and synergistically enabling effective chemodynamic therapy for enhancing the therapeutic effects of Sfb.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cancer, Hypoxia, and Metabolism · Nanoplatforms for cancer theranostics · Ferrocene Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Chemistry, Chemical Engineering and Materials Science, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Institute of Molecular and Nano Science
Shandong Normal University
Laoshan Laboratory
Funding
Natural Science Foundation of Shandong Province · Shandong Provincial Center for Fundamental Science Research
References (41)
Show source-provided references
1. 10.1001/jama.2015.1543110.1001/jama.2015.15431 ↗
2. 10.1186/s12951-022-01615-210.1186/s12951-022-01615-2 ↗
3. 10.3350/cmh.2023.012510.3350/cmh.2023.0125 ↗
4. 10.1038/s41571-024-00868-010.1038/s41571-024-00868-0 ↗
5. 10.1186/s13045-024-01647-110.1186/s13045-024-01647-1 ↗
6. 10.1016/j.biomaterials.2024.12306810.1016/j.biomaterials.2024.123068 ↗
7. 10.1002/cac2.1253610.1002/cac2.12536 ↗
8. 10.1001/jamaoncol.2023.267710.1001/jamaoncol.2023.2677 ↗
9. 10.1016/j.jhep.2024.05.03710.1016/j.jhep.2024.05.037 ↗
10. 10.1038/s41575-022-00704-910.1038/s41575-022-00704-9 ↗
11. 10.1001/jama.2016.2126610.1001/jama.2016.21266 ↗
12. 10.1186/s12943-024-02101-z10.1186/s12943-024-02101-z ↗
13. 10.1016/j.ccell.2024.01.00710.1016/j.ccell.2024.01.007 ↗
14. 10.1016/j.canlet.2023.21610610.1016/j.canlet.2023.216106 ↗
15. 10.1038/s41591-024-02824-y10.1038/s41591-024-02824-y ↗
16. 10.1186/s12943-025-02238-510.1186/s12943-025-02238-5 ↗
17. 10.1038/s41392-024-01963-510.1038/s41392-024-01963-5 ↗
18. 10.1016/j.jhep.2018.05.03410.1016/j.jhep.2018.05.034 ↗
19. 10.1038/s41467-019-12606-710.1038/s41467-019-12606-7 ↗
20. 10.1186/s12951-021-00989-z10.1186/s12951-021-00989-z ↗
21. 10.1186/s12964-024-01957-410.1186/s12964-024-01957-4 ↗
22. 10.1186/s13045-024-01634-610.1186/s13045-024-01634-6 ↗
23. 10.1016/j.cej.2024.15723110.1016/j.cej.2024.157231 ↗
24. 10.1016/j.jconrel.2025.01.07410.1016/j.jconrel.2025.01.074 ↗
25. 10.1021/acs.jmedchem.2c0088010.1021/acs.jmedchem.2c00880 ↗
26. 10.1002/adma.20180300110.1002/adma.201803001 ↗
27. 10.1039/D2CC04777B10.1039/D2CC04777B ↗
28. 10.1039/D2CC04238J10.1039/D2CC04238J ↗
29. 10.1021/acsnano.3c1118610.1021/acsnano.3c11186 ↗
30. 10.1016/j.cclet.2024.11080810.1016/j.cclet.2024.110808 ↗
31. 10.7150/thno.10169710.7150/thno.101697 ↗
32. 10.1002/anie.20231815510.1002/anie.202318155 ↗
33. 10.1186/s12951-025-03202-710.1186/s12951-025-03202-7 ↗
34. 10.1016/j.snb.2021.13105110.1016/j.snb.2021.131051 ↗
35. 10.1038/s41467-019-09566-310.1038/s41467-019-09566-3 ↗
36. 10.1039/D5CC05197E10.1039/D5CC05197E ↗
37. 10.1002/anie.20200418010.1002/anie.202004180 ↗
38. 10.1002/anie.20221085610.1002/anie.202210856 ↗
39. 10.1016/j.ijbiomac.2024.13694310.1016/j.ijbiomac.2024.136943 ↗
40. 10.1038/nrclinonc.2017.4410.1038/nrclinonc.2017.44 ↗
41. 10.1186/s12964-024-01522-z10.1186/s12964-024-01522-z ↗